23andMe founder Anne Wojcicki will regain control of embattled DNA company after all

23andMe founder Anne Wojcicki is poised to regain control of the bankrupt DNA testing company through her nonprofit, TTAM Research Institute, with a $305 million bid after Regeneron declined to counter. A bankruptcy judge is set to consider the deal on June 17, 2025. Wojcicki's plan involves maintaining customer data and privacy protections, including allowing data deletion and establishing a Consumer Privacy Advocacy Board, following a turbulent period for 23andMe marked by a data breach and layoffs.

Analysis

Anne Wojcicki, founder of 23andMe, is positioned to regain control of the company's assets via her nonprofit, TTAM Research Institute, following a $305 million offer in the bankruptcy auction, effectively outbidding Regeneron's initial $256 million proposal. Regeneron (REGN) opted not to submit a counter-offer that would have needed to exceed TTAM's bid by at least $10 million, leading to TTAM's likely success pending a bankruptcy judge's approval, with a hearing scheduled for June 17, 2025. This development occurs after 23andMe's March 2025 bankruptcy filing, which was preceded by a turbulent period including a significant data breach in 2023 and mass layoffs impacting 40% of staff in 2024. Wojcicki's stated intention is to continue 23andMe's mission with a reinforced commitment to customer data privacy, including provisions for data deletion, research opt-outs, a new Consumer Privacy Advocacy Board, and a pledge not to transfer genetic data in any subsequent insolvency unless the buyer adheres to identical privacy protections. This focus on privacy contrasts with Regeneron's reported interest in leveraging the genetic data for drug target identification. While the general sentiment surrounding Wojcicki's potential return is moderately positive with an optimistic tone, the broader market impact score is low at 0.3; conversely, sentiment specifically for Regeneron is negative (-0.4) following its withdrawal from the bidding.

Key Decisions for Investors

• Investors in Regeneron (REGN) should assess the impact of its decision to not pursue the 23andMe acquisition further, which could indicate either disciplined capital allocation or a re-evaluation of this specific asset's strategic fit for its R&D pipeline.
• The successful bid by TTAM Research Institute, driven by 23andMe's founder, underscores the persistent value attributed to genetic data assets and the critical role of data privacy commitments in rebuilding trust and value, particularly for entities emerging from financial distress.
• Market participants should monitor the outcome of the June 17, 2025, court hearing and any subsequent strategic announcements from TTAM concerning 23andMe's operational model, especially how it will balance research objectives with enhanced consumer privacy safeguards under new leadership.